



Louisiana Board of Pharmacy
3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Minutes

DRAFT

Regular Meeting

Thursday, August 13, 2020 at 9:00 a.m.

Location:

Videoconference

Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
45		
46		
47		
48		
49	1. Call to Order	03
50	2. Quorum Call	03
51	3. Call for Additional Agenda Items & Adoption of Agenda	06
52	4. Consideration of Draft Minutes from Previous Meeting	06
53	5. Report on Action Items	06
54	6. Confirmation of Acts	06
55	7. Opportunity for Public Comment	07
56	8. Special Orders of the Day	10
57	9. Committee Reports	
58	A. Finance	10
59	B. Application Review	11
60	C. Reciprocity	11
61	D. Violations	11
62	E. Impairment	15
63	F. Reinstatement	16
64	G. Tripartite	19
65	H. Regulation Revision	19
66	I. Executive	25
67	10. Staff Reports	
68	J. Assistant Executive Director	27
69	K. General Counsel	29
70	L. Executive Director	31
71	11. Request for Opinion: Delivery of Dispense Prescriptions to Lockers for Employees	33
72		
73	12. New Agenda Items Added During Meeting	33
74	13. Announcements	33
75	14. Adjourn	33
76		
77		
78		
79		
80		
81		
82		
83		
84		
85		
86		
87		
88		
89		
90		
91		

92 A regular meeting of the Louisiana Board of Pharmacy was held on Thursday, August
93 13, 2020 by videoconference. As noted on the meeting agenda, the Board certified it
94 could not achieve an in-person quorum due to the provisions of *Governor's*
95 *Proclamation No. 96 JBE 2020 ~ COVID-19 Public Health Emergency / Renewal of*
96 *Phase 2 of Resilient Louisiana*. Therefore, as permitted by R.S. 42:17.1, the Board
97 elected to conduct its meeting by videoconference.

98

99 *1. Call to Order*

100 Mr. Carl Aron, President, called the meeting to order at 9:05 a.m.

101

102 Mr. Aron informed the members and guests that the petitioner for Agenda Item 11, who
103 had requested an opinion relative to the delivery of dispensed prescriptions to lockers
104 for employees, had just withdrawn their request. He indicated that if anyone had joined
105 the call in connection with that request, he wanted them to know the matter would not
106 be considered that day.

107

108 *2. Quorum Call*

109 Mr. Aron called upon the Executive Director, Mr. Malcolm Broussard, to call the roll of
110 members to establish a quorum.

111

112 **Members Present:**

- 113 Mr. Carl W. Aron
- 114 Mr. Allen W. Cassidy, Jr.
- 115 Dr. J. Robert Cloud
- 116 Mr. David A. Darce
- 117 Ms. Jacqueline L. Hall
- 118 Mr. Richard M. Indovina, Jr.
- 119 Mr. Kevin LaGrange
- 120 Mr. Robert C. LeBas
- 121 Mr. Richard Mannino
- 122 Mr. Marty R. McKay
- 123 Mr. Anthony G. Mercante

124 Mr. Blake P. Pitre
125 Mr. Don L. Resweber
126 Mr. Douglas E. Robichaux (late arrival)
127 Dr. Raymond J. Strong (late arrival)
128 Mr. Rhonny K. Valentine (late arrival)

129

130 **Staff Present:**

131 Mr. Malcolm J. Broussard, Executive Director
132 Mr. Carlos M. Finalet, III, General Counsel
133 Mr. M. Joseph Fontenot, Assistant Executive Director
134 Ms. Kelley L. Villeneuve, Office Manager
135 Mr. Benjamin S. Whaley, Chief Compliance Officer
136 Mr. Cary D. Aaron, Compliance Officer
137 Mr. Daniel M. Dennis, Compliance Officer
138 Ms. Nicole L. Gross, Compliance Officer
139 Ms. Alicia P. Harris, Compliance Officer
140 Ms. Becky C. Parker, Compliance Officer
141 Mr. Huey J. Savoie, Compliance Officer

142

143 **Guests:**

144 Mr. Richard A. Soileau
145 Dr. Angelle M. Huff
146 Mr. Ben Sims
147 Ms. Brandi Armand
148 Mr. William C. Jones
149 Ms. Chris B. Melancon
150 Mr. Christopher LaGrange
151 Mr. David J. Bares
152 Ms. Diane M. Milano
153 Mr. Don Caffery
154 Dr. Dwana S. Day
155 Ms. Elise Rigby

156 Ms. Emily Haugh
157 Mr. Errol A. Duplantis, Jr.
158 Dr. Heather N. Maturin
159 Mr. Jeff Brown
160 Mr. H. Bernard LeBas
161 Dr. Janet L. Y. White
162 Dr. Jessica Adams
163 Dr. John Rocchio
164 Mr. Johnny Staub
165 Dr. Justin M. Scalfano
166 Mr. Russell Champagne
167 Ms. Penny Scruggins
168 Mr. Kenneth Dietz
169 Dr. Lorri Walmsley
170 Mr. Mark Johnston
171 Ms. Mary Staples
172 Dr. Michael B. Cockerham
173 Ms. Faith N. Hollier
174 Mr. Patrick K. Brian
175 Mr. Paul D. Menasco
176 Dr. Robert Geddes
177 Mr. Robert Sonnier
178 Dr. Ryan M. Burke
179 Dr. Sarah A. Mercante
180 Ms. Shelly Dupre
181 Ms. Stacy Hall
182 Dr. Tiffany T. Nguyen
183 Mr. Tim Frost
184 Mr. Thomas L. Martin

185
186 Mr. Broussard certified Mr. Robichaux, Dr. Strong, and Mr. Valentine did not reply to the
187 quorum call; however, the remaining 13 members were present, constituting a quorum

188 for the conduct of official business.

189

190 *3. Call for Additional Agenda Items & Adoption of Agenda*

191 Mr. Aron asked if there were any additional agenda items to be added. None were
192 requested. With no requests to amend the agenda, and without objection, the members
193 adopted the posted agenda dated August 11, 2020. Mr. Aron requested authority to re-
194 order the agenda as may become necessary and there were no objections to that
195 request.

196

197 *4. Consideration of Minutes*

198 Mr. Aron reminded the members they had received the draft minutes from the Special
199 Board Meeting on July 28, 2020 held by videoconference. With no objections, he
200 waived the reading of the draft minutes. With no requests for amendment or any
201 objection to their approval, Mr. Aron declared the minutes were approved as presented.

202

203 *5. Report on Action Items*

204 Mr. Aron called on Mr. Broussard for the report. Mr. Broussard directed the members to
205 a copy of the report in their meeting binder. There were no questions from the
206 members or guests.

207

208 *6. Confirmation of Acts*

209 Pursuant to Mr. Aron's declaration that the officers, committees, and executive director
210 had attended to the business of the Board since their last meeting in accordance with
211 policies and procedures previously approved by the Board, Mr. Pitre moved,

212 **Resolved**, that the actions taken and decisions made by the Board
213 officers, Board committees, and Executive Director in the general conduct
214 and transactions of Board business since July 28, 2020 are approved,
215 adopted, and ratified by the entire Board.

216 There were no member questions or public comments. The motion was adopted after a
217 unanimous roll call vote in the affirmative.

218

219

220 7. *Opportunity for Public Comment*

221 Mr. Aron reminded the members and guests the agenda for the meeting solicited public
222 comments on any agenda item prior to the meeting. Mr. Aron asked Mr. Broussard
223 whether any comments had been received. Mr. Broussard replied many comments had
224 been received prior to the meeting concerning two regulatory proposals scheduled for
225 consideration that day. He indicated they had been forwarded to the members and that
226 he was prepared to read them into the record. Mr. Aron directed that be done. Mr.
227 Broussard noted receipt of the following public comments prior to the meeting:

228 ➤ *Regulatory Proposal 454-2019-03 ~ Medication Administration (Draft #3)*

229 Dr. Robert Geddes, in favor

230 Mr. Jeenu Philip, in favor

231 Dr. Jarred Binney, opposed

232 Mr. Bradley DiGerolamo, opposed

233 ➤ *Regulatory Proposal 454-2019-13 ~ Staffing Ratios for Pharmacy Technicians*
234 *(Draft #2)*

235 Dr. My-Ngoc Tran, in favor

236 Dr. Nhu Pham, in favor

237 Dr. Jessica Vu, in favor

238 Dr. Tony Tran, in favor

239 Dr. Nikita Taylor, in favor

240 Dr. Edward Mendez, in favor

241 Dr. Nhi Tran, in favor

242 Dr. Brandi Marcade, in favor

243 Dr. Rebecca Han, in favor

244 Ms. Kim Wixson, opposed

245 Dr. Jonathan Bui, opposed

246 Ms. Christine Leger, opposed

247 Ms. Brooke Le, opposed

248 Mr. Errol Duplantis, opposed

249 Mr. Kevin Tomb, opposed

250 Dr. Forrest Fontenot, opposed

251 Ms. Temika Broussard, opposed

252 Dr. Marissa Rogers, opposed
253 Mr. Carl Savoie, opposed
254 Ms. Kimberly St. Marie, opposed
255 Mr. Don Frederick, opposed
256 Ms. Nikki Hollier, opposed
257 Ms. Tammy Stutes, opposed
258 Ms. Jennifer Stelly, opposed
259 Mr. William Jones, opposed
260 Ms. Jada Milton, opposed
261 Dr. Richard Djapni, opposed
262 Mr. Bart Enicke, opposed
263 Mr. Minh Nguyen, opposed
264 Ms. Shay Thompson, opposed
265 Mr. Ivan Landry, opposed
266 Ms. Cheramie Brewer, opposed
267 Ms. Estelle Guidry, opposed
268 Dr. Amy Tran, opposed
269 Mr. Robert Hollier, opposed
270 Mr. Tim Arceneaux, opposed
271 Ms. Meredith Stutes, opposed
272 Dr. Dana Antoon, opposed
273 Ms. Germaine Robinson, opposed
274 Ms. Jody Landry, opposed
275 Mr. Ken Savoie, opposed
276 Mr. Vince Bartley, opposed
277 Mr. Randal Girouard, opposed
278 Ms. Melissa Magee, opposed
279 Dr. Robert Holt, opposed
280 Ms. Melissa Stevens, opposed
281 Ms. Lauren Signorelli, opposed
282 Ms. Claire Ginfala, opposed
283 Ms. Veronica Comeaux, opposed

284 Ms. Sharron Ledoux, opposed
285 Dr. Brittany Combel, opposed
286 Ms. Loretta Boesing, opposed
287 Ms. Rachel LaCroix, opposed
288 Mr. Robert Rock, opposed
289 Mr. Nicholas LeBas, opposed
290 Ms. Pixie Carter, opposed
291 Mr. Jeenu Philip, in favor
292 Dr. Hai Bui, opposed
293 Dr. Manisha Paul, in favor
294 Ms. Mitzi Bates, opposed
295 Ms. Melissa Turner, opposed
296 Ms. Allison Seilhan, opposed
297 Ms. Shanna Marlowe, opposed
298 Mr. Anward Mayeaux, opposed
299 Ms. Renee Melancon, opposed
300 Ms. Dawn Higginbotham, opposed
301 Mr. Bert Blanchard, opposed
302 Ms. Savitra Collins, opposed
303 Dr. Shane Landry, opposed
304 Ms. Mary Kreedl, opposed
305 Dr. Johnathan Chang, in favor
306 Dr. Justin Scalfano, opposed
307 Ms. Lorna Gautreaux, opposed
308 Dr. Chelsie Head, opposed
309 Dr. Jarred Binney, opposed
310 Dr. Dung Nguyen, opposed
311 Ms. Lisa Cormier, opposed
312 Ms. Mary Greene, opposed
313 Mr. Bradley DiGerolamo, opposed
314
315 Mr. Aron then offered an opportunity for any public comments about any non-agenda

316 items; none were offered.

317

318 * *Statement of Purpose*

319 Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy
320 by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the
321 members to keep their legislative mandate in mind as they considered all the matters
322 before them.

323

324 8. *Special Orders of the Day*

325 There were no special orders for that day.

326

327 9. *Committee Reports*

328 A. *Finance Committee*

329 Mr. Aron recognized Mr. Russell Champagne and Ms. Penny Scruggins,
330 the certified public accountants with whom the Board has contracted for the
331 compilation and preparation of the quarterly and annual financial reports. Mr.
332 Champagned directed the members to a copy of the Final Report for Fiscal
333 Year 2019-2020 in their meeting binder. He reviewed the report and called
334 attention to unusual findings and factors influencing the Board's net position
335 at the end of that fiscal year. He replied to a question from Mr. Resweber
336 about the impact of the pension liability on other state agencies. Mr. Aron
337 expressed his appreciation to Mr. Champagne and Ms. Scruggins for their
338 assistance, noting the 20+ year history of their work with the Board. Mr. Aron
339 then called upon Mr. McKay for the committee report. Mr. McKay indicated
340 the committee members had reviewed the report during their meeting the
341 previous day and voted to recommend the approval of the report. He then
342 moved,

343 **Resolved**, to approve the *Final Report for Fiscal Year 2019-2020*
344 subject to legislative audit.

345 Mr. Broussard replied to a question from Mr. LaGrange about the recording of
346 the cost information for the medical marijuana tracking system. There were
347 no further questions or public comments. The motion was adopted after a

348 unanimous roll call vote in the affirmative. Mr. McKay then reported the
349 committee had also reviewed a staff proposal to amend the budget for the
350 current fiscal year, made some adjustments, then voted to recommend the
351 approval of that revised budget amendment. He then moved,

352 **Resolved**, to approve *Proposed Budget Amendment No. 1 for*
353 *Fiscal Year 2020-2021.*

354 There were no member questions or public comments. The motion was
355 adopted after a unanimous roll call vote in the affirmative.

356 Finally, on behalf of Committee Chair Blake Pitre, Mr. McKay expressed
357 his appreciation to the other committee members for their work the previous
358 day.

359
360 *B. Application Review Committee*

361 Mr. Aron noted the committee had not met since the previous Board
362 meeting. He informed the members he had appointed Mr. Doug Robichaux
363 to chair the committee, replacing Mr. Andy Soileau who had previously
364 chaired the committee and had completed his service to the Board on June
365 30.

366
367 *C. Reciprocity Committee*

368 Mr. Aron called upon Mr. Cassidy for the committee report. Mr. Cassidy
369 reported the staff had evaluated 42 applications for pharmacist licensure by
370 reciprocity since the last Board meeting and that none of them contained
371 information that warranted a committee level review. In conformance with
372 policies and procedures previously approved by the Board, the staff approved
373 the applications and issued the credentials. He then directed the members to
374 a list of the new pharmacists licensed by reciprocity in their meeting binder.

375 Finally, he closed his report with appreciation to the other committee
376 members for their ongoing efforts.

377
378 *D. Violations Committee*

379 Mr. Aron noted the committee chair, Mr. Richard Indovina, was traveling

380 that day, and although he was able to listen and vote was not able to read
381 reports into the record. Mr. Aron called upon the ranking member, Ms. Hall,
382 for the committee report. Ms. Hall reported the committee held preliminary
383 hearings on July 14-15, 2020 to consider their posted agenda which included
384 37 cases. Prior to the preliminary hearing, the committee chair granted
385 continuances to two of the respondents. Following their interviews and
386 deliberations at the hearing, the committee took no action with respect to six
387 of the respondents and issued non-disciplinary Letters of Noncompliance to
388 15 of the respondents. The committee offered proposed voluntary consent
389 agreements to the remaining 14 respondents, all of whom accepted their
390 proposed agreements. Ms. Hall then presented a synopsis of each of the
391 cases to the members. Following the conclusion of the case presentations,
392 Ms. Hall moved,

393 **Resolved**, to approve each of the 14 proposed voluntary consent
394 agreements itemized in the committee's report.

395 There were several questions concerning the same dispensing error at three
396 different pharmacies. Mr. Indovina indicated the committee determined the
397 error was primarily a workflow issue and applied the formal discipline to the
398 permits. The committee also issued non-disciplinary letters of noncompliance
399 to the pharmacists involved. The members requested a newsletter article
400 relative to pharmacists performing final checks for the dispensing of
401 reconstituted antibiotic suspensions. There was one public comment. The
402 motion was adopted after a unanimous roll call vote in the affirmative. The
403 consent agreements approved by the Board are itemized here:

404
405 **Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 04566 [Lafayette,**
406 **LA] (PHY.004057):** The Board assessed a fine of \$2,500 plus administrative
407 and investigative costs.

408
409 **Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 04192 [New Iberia,**
410 **LA] (PHY.003934):** The Board assessed a fine of \$2,500 plus administrative
411 and investigative costs.

412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443

Walgreen La. Co., Inc. d/b/a Walgreen Pharmacy No. 07166 [New Iberia, LA] (PHY.005012): The Board assessed a fine of \$2,500 plus administrative and investigative costs.

Louisiana CVS Pharmacy, LLC d/b/a CVS Pharmacy No. 5344 [Monroe, LA] (PHY.005775): The Board assessed a fine of \$60,000 plus administrative and investigative costs.

Central Rx Services, LLC d/b/a IngenioRx Specialty or CVS Specialty [Las Vegas, NV] (PHY.007919): The Board assessed a fine of \$50,000 plus administrative and investigative costs.

Wal-Mart Stores East, LP d/b/a Wal-Mart Pharmacy No. 10-5315 [Orlando, FL] (PHY.005063): The Board assessed a fine of \$10,000 plus administrative and investigative costs.

Charles Edward Maier (PST.015447): The Board issued a Letter of Reprimand, and further, assessed a fine of \$500 plus administrative and investigative costs.

Neumann's Pharmacy, LLC d/b/a Neumann's Pharmacy [Tallulah, LA] (PHY.006815): The Board assessed a fine of \$500 plus administrative and investigative costs.

Carla Lawrence Nordquist (SWP.000776 & PTC.021233): The Board issued a Letter of Reprimand, and further, assessed a fine of \$250 plus administrative costs.

Charbonnet Health, LLC d/b/a Charbonnet Family Pharmacy [New Orleans, LA] (PHY.007000): The Board assessed a fine of \$5,000 plus administrative and investigative costs.

444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475

Lynn Ann Johnson (PST.019325): The Board issued a Letter of Warning, and further, assessed a fine of \$250 plus administrative and investigative costs.

City Drug, Inc. d/b/a City Drug Store [Bunkie, LA] (PHY.004234): The Board assessed a fine of \$5,000 plus administrative and investigative costs.

The Compounding Center Pharmacy, LLC d/b/a The Compounding Center Pharmacy [Lafayette, LA] (PHY.005007): The Board suspended the permit for two years and stayed the execution of the suspension, then placed the permit on probation for two years effective August 13, 2020 subject to certain terms enumerated within the voluntary consent agreement, and further, assessed a fine of \$10,000 plus administrative and investigative costs.

Darrell Glenn Granger (PST.012078): The Board suspended the license for one year and stayed the execution of the suspension, then placed the license on probation for one year effective August 13, 2020 subject to certain terms enumerated within the voluntary consent agreement, and further, assessed administrative costs.

Ms. Hall then reported the committee had also performed its annual review of the committee's policies and procedures. Of the four policies reviewed, the committee voted to revise the policy relative to publication of final adverse actions. She then moved,

Resolved, to approve the proposed revision of *PPM.I.C.7.a ~ Publication of Final Adverse Actions.*

Mr. Broussard replied to a question from one member relative to publication of adverse actions related to impairment. There were no public comments. The motion was adopted after a unanimous roll call vote in the affirmative.

Ms. Hall then presented the Complaint Investigation Monitor Report. She

476 noted there were 179 open cases at the beginning of the previous fiscal year.
477 403 new cases were opened, and 400 cases were closed, leaving 182 open
478 cases to start the current fiscal year. She indicated for the 400 case
479 closures, the average time to complete an investigation was 50 days, and
480 further, 13 of those 400 case closures (3.3%) exceeded the policy threshold
481 of 180 days. She indicated the most common reason for an investigation to
482 exceed the policy threshold is a collaborative investigation with other state or
483 federal agencies and that another reason would be a nonresident case on
484 appeal.

485 She reported the committee's next preliminary hearing was scheduled for
486 September 15 to consider the 24 cases posted on that agenda.

487 Finally, she concluded the committee report with appreciation to the other
488 committee members for their ongoing efforts.

489 490 *E. Impairment Committee*

491 Mr. Aron called upon Ms. Hall for the committee report. Ms. Hall reported
492 the committee met on August 11 to consider four referrals from the staff –
493 one petition for modification of previous orders, one application for a new
494 credential, and two cases for informal conference. Following their interviews
495 of the applicants and subsequent deliberations, the committee deferred
496 consideration of the application for a new credential pending receipt of the
497 results of a medical evaluation. With respect to one of the respondents
498 scheduled for an informal conference, that person did not appear; therefore,
499 the emergency summary suspension previously issued will remain in effect
500 until the respondent does appear at a future meeting. Ms. Hall then
501 presented the following recommendations to the members for their
502 consideration.

503
504 **Kevin Trenouth Kellow (PST.019095):** Ms. Hall moved to grant the
505 applicant's request for modification of previous orders to terminate the
506 probationary period originally scheduled to conclude on May 10, 2022. There
507 were no member questions or public comments. The motion was adopted

508 after a unanimous roll call vote in the affirmative. The Board granted the
509 applicant's request for modification of previous orders, removed all
510 probationary terms, then restored the license to active and unrestricted
511 status.

512
513 **Roy Kirk Fisher, Jr. (PST.018600):** Ms. Hall moved to grant the applicant's
514 request to reinstate the previously suspended license. There were no
515 member questions or public comments. The motion was adopted after a
516 unanimous roll call vote in the affirmative. The Board granted his request for
517 reinstatement of the previously suspended license, converted the duration of
518 the suspensive period from an indefinite term to a term of 15 years and
519 stayed the execution of the suspension, then placed the license on probation
520 for 15 years effective August 13, 2020 subject to certain terms enumerated
521 within the voluntary consent agreement.

522
523 Finally, Ms. Hall closed her report with appreciation to her fellow
524 committee members for their work on August 11.

525
526 *F. Reinstatement Committee*

527 Mr. Aron informed the members he had appointed Mr. Rhonny Valentine
528 to chair the committee, replacing Mr. Ron Moore who completed his service
529 to the Board on June 30, 2020. Mr. Aron then called upon Mr. Valentine for
530 the committee report. Mr. Valentine reported the committee met on August
531 11 to consider six referrals from the staff – one petition for reinstatement of a
532 suspended credential, three petitions for reinstatement of lapsed credentials
533 and two requests for modification of previous orders. Following their
534 interviews of the applicants and subsequent deliberations, the committee
535 developed recommendations for each of the applicants. Mr. Valentine
536 presented the following recommendations to the members for their
537 consideration.

540 **Chau Thai Nguyen (PST.022285):** Mr. Valentine moved to grant the
541 applicant's request for reinstatement of the suspended license. There were
542 no member questions or public comments. The motion was adopted after a
543 unanimous roll call vote in the affirmative. The Board granted the applicant's
544 request for reinstatement of the previously suspended license, then restored
545 the license to active and unrestricted status.

546
547 **Sarah Elizabeth Logue (CPT.009972):** Mr. Valentine moved to grant the
548 applicant's request for reinstatement of the lapsed certificate contingent upon
549 the satisfaction of certain requirements prior to August 13, 2022. There were
550 no member questions or public comments. The motion was adopted after a
551 unanimous roll call vote in the affirmative. The Board granted the applicant's
552 request for reinstatement of the lapsed certificate contingent upon the
553 satisfaction of the following requirements prior to August 13, 2022: (1) the
554 acquisition of at least 250 hours of updated practical experience, to be earned
555 under the authority of a Special Work Permit to be obtained from the Board
556 office, (2) a letter of competency from the pharmacist supervising the updated
557 practical experience, and (3) the acquisition of 10 hours of ACPE-accredited
558 technician-specific continuing pharmacy education (CPE), not to include the
559 CPE hours submitted as part of the reinstatement application.

560
561 **Eugenia Brignac Kocke (CPT.001732):** Mr. Valentine moved to grant the
562 applicant's request for reinstatement of the lapsed certificate contingent upon
563 the satisfaction of certain requirements prior to August 13, 2022. Mr. Finalet
564 replied to a question that the applicant had previously passed a pharmacy
565 technician certification examination. There were no public comments. The
566 motion was adopted after a unanimous roll call vote in the affirmative. The
567 Board granted the applicant's request for reinstatement of the lapsed
568 certificate contingent upon the satisfaction of the following requirements prior
569 to August 13, 2022: (1) the acquisition of at least 250 hours of updated
570 practical experience, to be earned under the authority of a Special Work
571 Permit to be obtained from the Board office, (2) a letter of competency from

572 the pharmacist supervising the updated practical experience, and (3) the
573 acquisition of 10 hours of ACPE-accredited technician-specific continuing
574 pharmacy education (CPE), not to include the CPE hours submitted as part of
575 the reinstatement application.

576
577 **Lindy Reeves Fordham (CPT.004211):** Mr. Valentine moved to grant the
578 applicant's request for reinstatement of the lapsed certificate contingent upon
579 the satisfaction of certain requirements prior to August 13, 2022. There were
580 no member questions or public comments. The motion was adopted after a
581 unanimous roll call vote in the affirmative. The Board granted the applicant's
582 request for reinstatement of the lapsed certificate contingent upon the
583 satisfaction of the following requirements prior to August 13, 2022: (1) the
584 acquisition of at least 250 hours of updated practical experience, to be earned
585 under the authority of a Special Work Permit to be obtained from the Board
586 office, (2) a letter of competency from the pharmacist supervising the updated
587 practical experience, (3) the acquisition of 10 hours of ACPE-accredited
588 technician-specific continuing pharmacy education (CPE), not to include the
589 CPE hours submitted as part of the reinstatement application, and (4)
590 successful completion of a board-approved pharmacy technician certification
591 examination.

592
593 **Kimberly Juanita Murphy (PST.016122):** Mr. Valentine moved to deny the
594 applicant's request for modification of previous orders to remove the restriction
595 which prevents her from accepting an appointment as the pharmacist-in-
596 charge of a pharmacy. There were no member questions or public comments.
597 The motion was adopted after a unanimous roll call vote in the affirmative.
598 The Board denied the applicant's request for modification of previous orders.

599
600 **Noah's Pharmacy, LLC d/b/a Noah's Pharmacy [Brusly, LA]**
601 **(CDS.039326-PHY):** Mr. Valentine moved to deny the applicant's request for
602 reinstatement of the controlled substance privileges for the pharmacy. There
603 were no member questions or public comments. The motion was adopted

604 after a unanimous roll call vote in the affirmative. The Board denied the
605 request for reinstatement of controlled substance privileges for the pharmacy.
606

607 Mr. Valentine closed his report with appreciation to the other committee
608 members for their work during the committee meeting on August 11.
609

610 *G. Tripartite Committee*

611 Mr. Aron noted that Mr. Resweber is the committee chair. He also noted
612 the committee had not met recently due to the absence of an assigned topic
613 from the Board.
614

615 At this point, Mr. Aron declared a brief recess. It was noted the members recessed at
616 10:50 am and then reconvened at 11:05 am. Mr. Aron resumed the sequence of
617 committee reports.
618

619 *H. Regulation Revision Committee*

620 Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay
621 reported the committee met on July 16 to consider the items on their posted
622 agenda. He reminded the members one of the committee recommendations
623 was a regulatory proposal relative to marijuana recommendations and that
624 the Board had held a special meeting on July 28 to act on that regulatory
625 proposal. He reported the was prepared to present the other regulatory
626 proposals approved during that July 16 meeting.

627 Mr. Aron requested Mr. McKay adjust the sequence of the items in his
628 report to prioritize the regulatory proposals relative to medication
629 administration and staffing ratios for pharmacy technicians. Mr. Aron
630 indicated a member had previously indicated his need to depart the meeting
631 early but wanted to participate in the discussion and decision for those two
632 proposals.

633 Mr. McKay reported the receipt of a formal request for rulemaking just
634 prior to the July 16 meeting to authorize pharmacy technicians to administer
635 immunizations, and further, to issue that authority as an emergency rule in

636 light of the current public health emergency. In order to provide a
637 mechanism for the Board to respond to the formal request, Mr. McKay
638 reported the committee re-visited a regulatory proposal previously approved
639 by the Board, *Regulatory Proposal 454-2019-03 ~ Medication Administration*
640 *(Draft #2)*, added pharmacy technicians to the proposal to authorize them to
641 qualify for and receive a medication administration registration, then voted to
642 recommend the approval of Draft #3 of that proposal. He then moved,

643 **Resolved**, to approve *Regulatory Proposal 454-2019-03 ~*
644 *Medication Administration (Draft #3)*, and further, to authorize the
645 Executive Director to promulgate the proposed rule change upon
646 the instruction of the President, and further, to authorize the
647 President to approve acceptable amendments as may become
648 necessary during the promulgation process.

649 There were comments from several members and guests. The motion failed
650 after a majority roll call vote in the negative. Voting in favor were Ms. Hall,
651 Mr. Indovina, and Dr. Strong; voting in opposition were Mr. Cassidy, Dr.
652 Cloud, Mr. Darce, Mr. LaGrange, Mr. LeBas, Mr. Mannino, Mr. McKay, Mr.
653 Mercante, Mr. Pitre, Mr. Resweber, Mr. Robichaux, and Mr. Valentine.

654 Mr. McKay reported the committee agenda on July 16 had two items
655 remaining from Regulatory Project 454-2019 and the committee developed
656 recommendations for both of those items. He then moved,

657 **Resolved**, to reject *Regulatory Proposal 454-2019-13 ~ Staffing*
658 *Ratios for Pharmacy Technicians (Draft #2)*, and further, to direct
659 the Executive Director to notify the commentator requesting the
660 change.

661 There were comments from several members and guests. The motion was
662 adopted after a unanimous roll call vote in the affirmative.

663 Mr. McKay reminded the members they had previously approved two
664 separate pilot projects relative to automated medication systems – the first
665 relative to remote dispensing systems in unlicensed healthcare facilities and
666 the second relative to automated medication systems in correctional
667 facilities. He reported the committee had relied on results from the projects

668 in their development of the regulatory proposal currently in process, and
669 further, recommended the continuation of the authority for the pilot projects
670 until the rule was promulgated. He indicated the authority for both pilot
671 projects was scheduled to expire on August 31, 2020. He then moved,

672 **Resolved**, to extend the authority for the following pilot projects: (1)
673 Remote Dispensing System by Highgate Ventures, LLC; and (2)
674 Automated Medication System by Institutional Pharmacies of
675 Louisiana, LLC; and further, to extend the authority for each of the
676 projects until the earliest of the following dates: (a) promulgation of
677 the final rule in *Regulatory Project 2020-2 ~ Automated Medication*
678 *Systems*, or (b) August 31, 2021.

679 There were no member questions or public comments. The motion was
680 adopted after a unanimous roll call vote in the affirmative.

681 Mr. McKay returned to the sequence of regulatory proposals noted on
682 the agenda. He noted the final remaining item from Regulatory Project 454-
683 2019 relative to telepharmacy dispensing sites. He then moved,

684 **Resolved**, to approve *Regulatory Proposal 454-2019-34 ~*
685 *Telepharmacy Dispensing Site (Draft #3)*, and further, to authorize
686 the Executive Director to promulgate the proposed rule change
687 upon the instruction of the President, and further, to authorize the
688 President to approve acceptable amendments as may become
689 necessary during the promulgation process.

690 There were no member questions or public comments. The motion was
691 adopted after a unanimous roll call vote in the affirmative.

692 Mr. McKay reminded the members of the timeline for Regulatory Project
693 454-2019. He reported Act 454 of the 2018 Legislature required all
694 rulemaking agencies in the state to conduct a public hearing on the entirety
695 of its rules to solicit public comments on any existing rules believed to be
696 contrary to law, outdated, unnecessary, overly complex, or burdensome and
697 then respond to those comments. Further, every state agency was required
698 to conduct their first such public hearing prior to January 1, 2020 and at
699 least once during every six-year period thereafter. Mr. McKay reminded the

700 members the Board held that first public hearing in June 2019. The Board
701 evaluated the 48 comments received during their subsequent meeting in
702 August 2019. The Board noted some of the requests were already
703 underway in the rulemaking process and also denied some requests. The
704 Board referred 20 items to the committee, and as of that day, had returned
705 all of the items back to the Board. Since some of the requested items will
706 amend the same chapter of rules, staff has held all of the items pending the
707 committee's completion of its work. He reported staff will now begin the
708 formal promulgation process for all of the items approved by the Board. He
709 also reported staff had set a calendar note the Board must hold its next Act
710 454 public hearing no later than June 26, 2025.

711 Mr. McKay reminded the members of their temporary waiver of the rule for
712 the delivery of dispensed marijuana products. He noted that issue had been
713 referred to the committee just prior to the public health emergency and the
714 committee voted to recommend the approval of a regulatory proposal for
715 that rule change. He then moved,

716 **Resolved**, to approve *Regulatory Proposal 2020-G ~ Delivery of*
717 *Dispensed Marijuana Products (Draft #1)*, and further, to authorize
718 the Executive Director to promulgate the proposed rule change
719 upon the instruction of the President, and further, to authorize the
720 President to approve acceptable amendments as may become
721 necessary during the promulgation process.

722 There were no member questions or public comments. The motion was
723 adopted after a unanimous roll call vote in the affirmative.

724 Mr. McKay reported the staff's discovery of a conflict in the rules relative
725 to the labeling of marijuana products by the producer, more specifically in
726 the prescribed text required to appear on the product labels. The state
727 agriculture department has slightly different wording required in their rules.
728 Since the producers are regulated by the state agriculture department, the
729 committee recommended resolving the conflict by amending the Board's
730 rules to require compliance with the agriculture department's rules. He then
731 moved,

732 **Resolved**, to approve *Regulatory Proposal 2020-H ~ Marijuana*
733 *Product Labeling (Draft #2)*, and further, to authorize the Executive
734 Director to promulgate the proposed rule change upon the
735 instruction of the President, and further, to authorize the President
736 to approve acceptable amendments as may become necessary
737 during the promulgation process.

738 There were no member questions or public comments. The motion was
739 adopted after a unanimous roll call vote in the affirmative.

740 Mr. McKay reported staff's review of the state of emergency rule and a
741 recommendation to increase the maximum quantity that could be dispensed
742 for an emergency prescription. The committee voted to recommend the
743 approval of that proposal. He then moved,

744 **Resolved**, to approve *Regulatory Proposal 2020-J ~ Emergency*
745 *Dispensing (Draft #2)*, and further, to authorize the Executive
746 Director to promulgate the proposed rule change upon the
747 instruction of the President, and further, to authorize the President
748 to approve acceptable amendments as may become necessary
749 during the promulgation process.

750 There were no member questions or public comments. The motion was
751 adopted after a unanimous roll call vote in the affirmative.

752 Mr. McKay reported the receipt in April of a formal request for rulemaking
753 to add a requirement for access to veterinary drug reference materials in the
754 section of rules for pharmacies if their practice includes the dispensing of
755 veterinary prescriptions. The committee agreed with the request and voted
756 to recommend approval of the proposal. Mr. McKay then moved,

757 **Resolved**, to approve *Regulatory Proposal 2020-K ~ Veterinary*
758 *Drug Reference (Draft #1)*, and further, to authorize the Executive
759 Director to promulgate the proposed rule change upon the
760 instruction of the President, and further, to authorize the President
761 to approve acceptable amendments as may become necessary
762 during the promulgation process.

763 There were comments from both members and guests. The motion was

764 adopted after a unanimous roll call vote in the affirmative.

765 Mr. McKay reminded the members of their referral of Act 200 of the 2020
766 Legislature, relative to occupational licensing of military families, to the
767 committee. The committee reviewed a staff proposal and voted to
768 recommend its approval. Mr. McKay moved,

769 **Resolved**, to approve *Regulatory Proposal 2020-M ~ Occupational*
770 *Licensing for Military Families (Draft #1)*, and further, to authorize
771 the Executive Director to promulgate the proposed rule change
772 upon the instruction of the President, and further, to authorize the
773 President to approve acceptable amendments as may become
774 necessary during the promulgation process.

775 During the discussion, Mr. McKay noted some drafting errors and offered an
776 amendment to correct the inaccurate references to pharmacists and
777 pharmacist licenses in the section of rule relative to pharmacy technicians.
778 There were no further member questions or public comments. The motion to
779 approve the amendments was adopted after a unanimous roll call vote in the
780 affirmative. He then moved to approve the amended proposal re-titled
781 *Regulatory Proposal 2020-M ~ Occupational Licensing for Military Families*
782 *(Draft #2)*. There were no further member questions or public comments.
783 The motion to approve the amended proposal was adopted after a
784 unanimous roll call vote in the affirmative.

785 Mr. McKay reminded the members of their decision during the June 25
786 Board meeting to refer Regulatory Project 2020-2 ~ Automated Medication
787 Systems and the underlying Regulatory Proposal 2019-C (Draft #7) back to
788 the committee based on comments received during the May 29 public
789 hearing. The committee approved changes to the same three areas
790 discussed during that June 25 meeting and then voted to recommend the
791 approval of the revised proposal to the Board. Mr. McKay then moved,

792 **Resolved**, to approve *Regulatory Proposal 2019-C ~ Automated*
793 *Medication Systems (Draft #8)*, and further, to authorize the
794 Executive Director to promulgate the proposed rule change upon
795 the instruction of the President, and further, to authorize the

796 President to approve acceptable amendments as may become
797 necessary during the promulgation process.

798 Mr. McKay replied to questions from several members. There were no
799 public comments. The motion was adopted after a unanimous roll call vote
800 in the affirmative.

801 Finally, Mr. McKay closed his report with appreciation to the committee
802 members and staff for their ongoing efforts.

803

804 *I. Executive Committee*

805 Mr. Aron reported the committee had met the previous day to consider the
806 items on their posted agenda. The committee reviewed the Compliance
807 Questionnaire developed by staff as part of the financial audit currently in
808 process. The committee also reviewed the proposed memorandum of
809 understanding (MOU) with the federal Food & Drug Administration (FDA)
810 relative to the distribution of compounded human drug products by
811 pharmacies. The committee reviewed a regulatory proposal relative to the
812 creation of a controlled dangerous substance license for hemp facilities.
813 Finally, the committee reviewed a revised proposal from Metrc relative to the
814 Louisiana Medical Marijuana Tracking System (LMMTS). He indicated Mr.
815 McKay was prepared to offer motions on behalf of the committee.

816 Mr. Aron reported staff had developed the compliance questionnaire
817 required as part of the annual financial audit. Mr. McKay then moved,

818 **Resolved**, to approve the *Compliance Questionnaire for the 2020*
819 *Financial Audit*.

820 There were no member questions or public comments. The motion was
821 adopted after a unanimous roll call vote in the affirmative.

822 Mr. Aron reported the committee had voted to recommend the approval of
823 the pending MOU with the FDA. Mr. McKay moved,

824 **Resolved**, to authorize the Louisiana Board of Pharmacy to enter
825 into the *Memorandum of Understanding Addressing Certain*
826 *Distributions of Compounded Human Drug Products with the U.S.*
827 *Food and Drug Administration*.

828 During the discussion, a question arose as to the potential burden of the
829 required data collection and whether that burden should be borne by the
830 Board's compliance officers or the pharmacies engaged in the compounding
831 activity. Mr. Aron suggested the Regulation Revision Committee should
832 review the matter and determine whether a regulatory proposal should be
833 developed. Mr. McKay withdrew his motion, and Mr. Aron referred the MOU
834 to the Regulation Revision Committee.

835 Mr. Aron reminded the members of the recent legislation creating the
836 statewide agricultural hemp industry. Hemp growers need to test their crop
837 materials to ensure the plants do not contain an impermissible level of
838 tetrahydrocannabinol. The federal legislation on this topic requires the hemp
839 grower to obtain a federal DEA registration. In order to qualify for the DEA
840 registration, the hemp grower must first obtain a state controlled substance
841 license. Mr. Aron indicated the Regulation Revision committee had
842 preliminary discussion with a stakeholder but additional clarification was
843 necessary. Since that discussion, the legislature revised the industrial hemp
844 law in the 2020 legislative session. Staff then worked with the Dept. of
845 Agriculture & Forestry as well as the Dept. of Health and other stakeholders
846 to draft a regulatory proposal to create a classification of CDS license for
847 hemp growers and other stakeholders in that industry. Mr. Aron reported the
848 Executive Committee reviewed Draft #2 and requested some minor changes
849 and then voted to recommend the approval of Draft #3. Mr. McKay then
850 moved,

851 **Resolved**, to approve *Regulatory Proposal 2020-D ~ CDS License*
852 *for Hemp Facility (Draft #3)*, and further, to authorize the Executive
853 Director to promulgate the proposed rule change upon the
854 instruction of the President, and further, to authorize the President
855 to approve acceptable amendments as may become necessary
856 during the promulgation process.

857 There were no member questions or public comments. The motion was
858 adopted after a unanimous roll call vote in the affirmative.

859 Mr. Aron reminded the members of their previous discussion of the

860 Board's cost to access the Louisiana Medical Marijuana Tracking System
861 (LMMTS). He reported staff reached out to the vendor, Metrc, to inform them
862 the Board was not amenable to paying the same price as the previous year.
863 Mr. Aron reported receipt of a new proposal from Metrc with a significant
864 price reduction. Mr. McKay then moved,

865 **Resolved**, to renew the agreement with Metrc relative to Board
866 access to the Louisiana Medical Marijuana Tracking System
867 (LMMTS) for Fiscal Year 2020-2021 in an amount not to exceed
868 \$1,200.

869 There were no member questions or public comments. The motion was
870 adopted after a unanimous roll call vote in the affirmative.

871 Finally, Mr. Aron reported the committee discussed a staff report about the
872 distribution of pharmacist wall certificates as well as pharmacist gold
873 certificates. Since the public health emergency has prevented physical
874 meetings, the members have not been able to personally sign the certificates.
875 Therefore, staff have not been able to distribute those certificates in a timely
876 manner. The committee authorized staff to pursue the commercial printing of
877 the certificates with digital duplicates of the members' signatures.

878 Mr. Aron closed his report with appreciation for the other committee
879 members and their work the previous day.

880

881 10. Staff Reports

882 J. Report of Assistant Executive Director

883 Mr. Aron called upon Mr. Fontenot for his report. He directed the
884 members to the quarterly report of the prescription monitoring program,
885 detailing the prescription transaction counts as well as queries from
886 prescribers, dispensers, and law enforcement agencies. He called their
887 attention to a new portion of the report detailing information on marijuana
888 products dispensed in marijuana pharmacies. The members expressed
889 appreciation for the patient-based dispensing volume information. Mr.
890 Broussard reminded the members of the changes to the marijuana program
891 adopted by the 2020 Legislature and suggested the Board continue to collect

892 that patient-based information using the expanded diagnosis and physician
893 parameters in the 2020 legislation for approximately one year and then begin
894 the process to issue the tenth and final marijuana pharmacy permit.

895 Mr. Fontenot then directed the members to the requests from 31
896 pharmacies seeking a waiver from the duty to report zero prescription
897 transaction reports to the prescription monitoring program. Mr. McKay then
898 moved,

899 **Resolved**, to authorize the issuance of full PMP reporting waivers
900 to:

- 901 > PHY.008124-HOS – Acadian Medical Center Pharmacy (LA);
- 902 > PHY.008076-HOS – Alexandria Emergency Hospital (LA);
- 903 > PHY.008104-NR – AxivaRx of Kansas (KS);
- 904 > PHY.008095-NR – Biologics by McKesson (NC);
- 905 > PHY.008096-NR – Biologics by McKesson (NC);
- 906 > PHY.004451-NR – BioScrip Pharmacy Services (OH);
- 907 > PHY.008082-NR – Buy-Rite Drugs (AL);
- 908 > PHY.008058-NR – Cottrill's Pharmacy (NY)
- 909 > PHY.003542-RC – DCS-NO Pharmacy (LA);
- 910 > PHY.006269-RC – DCS-NO Pharmacy (LA);
- 911 > PHY.007403-RC – DCS-NO Pharmacy (LA);
- 912 > PHY.006270-RC – DCS-NO Pharmacy (LA);
- 913 > PHY.006841-RC – DCS-NO Pharmacy (LA);
- 914 > PHY.008092-NR – Deliverit Pharmacy Infusion Center (TX);
- 915 > PHY.005274-IR – Diabetes Mgt & Supplies Pharmacy (LA);
- 916 > PHY.008044-NR – Empower Pharmacy (TX);
- 917 > PHY.007530-NR – HCP Pharmacy (TX);
- 918 > PHY.008087-NR – Healix Infusion Therapy (TX);
- 919 > PHY.008049-NR – Holistic Pharmacy Service (TX);
- 920 > PHY.005985-NR – Home Med Pharmacy (IN);
- 921 > PHY.008075-NR – Humana Pharmacy (OH);
- 922 > PHY.008086-NR – Humana Pharmacy (AZ);
- 923 > PHY.008112-NR – Kroger Specialty Infusion (AL);

- 924 > PHY.008097-NR – MedWiseRx (AZ);
 - 925 > PHY.008038-SAT – Ochsner LSU Health Shreveport (LA);
 - 926 > PHY.008045-NR – PipelineRx (SC);
 - 927 > PHY.008070-NR – Premier Specialty Infusion (IL);
 - 928 > PHY.008106-NR – Simple Rx Pharmacy (TX);
 - 929 > PHY.008098-NR – Sortpak Pharmacy (CA);
 - 930 > PHY.008103-NR – Tulip Pharmacy (TX); and
 - 931 > PHY.008105-NR – Watson Rx Solutions (AL)
- 932 once they have executed the standard consent agreement for that
- 933 purpose.

934 There were no member questions or public comments. The motion was

935 adopted after a unanimous roll call vote in the affirmative.

936 Mr. Fontenot reviewed a reminder notice recently distributed to all

937 pharmacies relative to the requirement to report all butalbital dispensing to

938 the state prescription monitoring program. The notice addressed the

939 confusion that apparently existed among some pharmacies that only some

940 butalbital dispensing was reportable. The notice reminded pharmacies that

941 all butalbital products in Louisiana are classified as controlled substances or

942 drugs of concern; there are no butalbital products that are not one or the

943 other. Since both controlled substances and drugs of concern are reportable,

944 then all butalbital dispensing is reportable.

945 Mr. Fontenot then addressed another area of confusion among some

946 pharmacies relative to the reporting of certain veterinary prescriptions, more

947 particularly including the owner’s information as well as species codes in their

948 reports to the state prescription monitoring program.

949 Finally, Mr. Fontenot indicated completion of his report.

950

951 *K. Report of General Counsel*

952 Mr. Aron called upon Mr. Finalet for his report. Mr. Finalet informed the

953 members he had developed proposed voluntary consent agreements using

954 criteria previously approved by the Board’s Violations Committee and then

955 offered them to various respondents. He then presented eight proposed

956 voluntary consent agreements which had been accepted and signed by the
957 respondents. Mr. McKay moved to accept all eight of the proposed voluntary
958 consent agreements presented by Mr. Finalet. There were no member
959 questions or public comments. The motion was adopted after a unanimous
960 roll call vote in the affirmative. The consent agreements approved by the
961 Board are itemized here:

962
963 **Anh Thi Phuong Tran (PST.022162):** The Board accepted the voluntary
964 surrender, resulting in the active suspension of the license for an indefinite
965 period of time effective June 23, 2020.

966
967 **Tabitha Danielle Hatfield (CPT.012189):** The Board revoked the certificate
968 effective June 23, 2020, and further, permanently prohibited the acceptance
969 of any future reinstatement application or any other application for any
970 credential issued by the Board.

971
972 **Folse Pharmacy, Inc. d/b/a Folse Pharmacy [Marrero, LA] (CDS.038941-
973 PHY):** The Board accepted the voluntary surrender, resulting in the active
974 suspension of the CDS license for an indefinite period of time effective June
975 25, 2020.

976
977 **Patience Marie Viator Bergeron (PST.019238):** The Board accepted the
978 voluntary surrender, resulting in the active suspension of the license for an
979 indefinite period of time effective June 26, 2020.

980
981 **Cindy Stevens Rodrigue (CPT.001884):** The Board revoked the certificate
982 effective June 29, 2020, and further, permanently prohibited the acceptance
983 of any future reinstatement application or any other application for any
984 credential issued by the Board.

985
986 **Jasmine Noell Foster (CPT.009162):** The Board revoked the certificate
987 effective July 22, 2020, and further, permanently prohibited the acceptance of

988 any future reinstatement application or any other application for any
989 credential issued by the Board.

990
991 **Melissa Williams Richardson (PST.016774):** The Board accepted the
992 voluntary surrender, resulting in the active suspension of the license for an
993 indefinite period of time effective July 28, 2020.

994
995 **Brianna Arianna Brown (CPT.013373):** The Board issued a Letter of
996 Reprimand, and further, assessed a fine of \$250 plus administrative costs.

997
998 Finally, Mr. Finalet indicated the completion of his report.

999
1000 *L. Report of Executive Director*

1001 Mr. Aron called upon Mr. Broussard for his report. Mr. Broussard directed
1002 the members to his report in the meeting binder. He reviewed the following
1003 topics:

- 1004 • Meeting Activity
- 1005 • Reports
 - 1006 ➤ Internal Reports
 - 1007 Credentials Division
 - 1008 Census Report
 - 1009 Licensure Activity Report
 - 1010 Application Activity Report
 - 1011 Exceptions Report
 - 1012 Compliance Division
 - 1013 Census Report
 - 1014 Complaint Investigation Policy Monitor
 - 1015 Annual Statistical Report
 - 1016 ➤ External Reports
 - 1017 Administrative and Legislative Agency Reports
 - 1018 Annual Report

1020 Mr. Aron reminded the members the board's annual report is required to be
1021 distributed to the Governor's office as well as the legislative oversight
1022 committees, but that board approval is required to complete that process.

1023 Mr. Pitre then moved,

1024 **Resolved**, to approve the Board's *Annual Report for Fiscal Year*
1025 *2019-2020*, and further, to direct the Executive Director to submit
1026 the report to the Office of the Governor as well as the House and
1027 Senate Committees on Health & Welfare, and then to publish the
1028 report on the Board's website.

1029 There were no member questions or public comments. The motion was
1030 adopted after a unanimous roll call vote in the affirmative.

1031

1032 • Examinations

1033 MPJE

1034 NAPLEX

1035 ExCPT

1036 PTCE

1037 • Operations

1038 Credentials Division

1039 Compliance Division

1040 Administrative Division

1041 Marijuana Pharmacies

1042 • Regional & National Activities

1043 National Association of Boards of Pharmacy (NABP)

1044 NABP-AACP District 6

1045 MALTAGON

1046 • International Activities

1047 International Pharmaceutical Federation (FIP)

1048 World Health Professions Alliance (WHPA)

1049 dotPharmacy Verified Websites Program

1050

1051 Finally, Mr. Broussard indicated the completion of his report.

1052

1053 *11. Request for Opinion: Delivery of Dispensed Prescriptions to Lockers for*
1054 *Employees*

1055 Mr. Aron reminded the members the petitioner had withdrawn their request

1056

1057 *12. New Agenda Items Added During Meeting*

1058 No items were added to the agenda.

1059

1060 *13. Announcements*

1061 Mr. Aron directed the members to the announcements in their meeting binder. He
1062 announced the next regular meeting of the Board would be held in November.

1063

1064 *14. Adjourn*

1065 Having completed the tasks itemized on the posted agenda, with no further business
1066 pending before the Board, and without objection, Mr. Aron adjourned the meeting at
1067 2:10 p.m.

1068

1069 *Minutes prepared by Malcolm Broussard*

1070

1071 These minutes were approved by the Board during its meeting on _____.

1072

1073

1074 _____

1075 Richard M. Indovina, Jr.

1076 Secretary